Wang, Feng http://orcid.org/0000-0001-7668-9674
Jin, Ying http://orcid.org/0000-0001-7105-3052
Wang, Min
Luo, Hui-Yan http://orcid.org/0000-0001-6312-9299
Fang, Wei-Jia http://orcid.org/0000-0001-9849-347X
Wang, Ying-Nan
Chen, Yan-Xing
Huang, Run-Jie
Guan, Wen-Long
Li, Ji-Bin http://orcid.org/0000-0001-7632-3648
Li, Yu-Hong
Wang, Feng-Hua
Hu, Xiao-Hua
Zhang, Yan-Qiao
Qiu, Miao-Zhen
Liu, Lu-Lu
Wang, Zi-Xian
Ren, Chao
Wang, De-Shen
Zhang, Dong-Sheng
Wang, Zhi-Qiang
Liao, Wen-Ting http://orcid.org/0000-0003-4953-3134
Tian, Lin http://orcid.org/0000-0003-3661-4453
Zhao, Qi http://orcid.org/0000-0002-8683-6145
Xu, Rui-Hua http://orcid.org/0000-0001-9771-8534
Article History
Received: 30 July 2023
Accepted: 10 January 2024
First Online: 4 March 2024
Competing interests
: R.H.X. has served as a consulting or advisory role for Bristol-Myers Squibb, Merck Serono, Roche, Astellas, and AstraZeneca. The remaining authors delcare no competing interests.